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This paper outlines the BMT activity in India and
describes in some detail the transplant program at the
Christian Medical College, Vellore. In September 2005,
data from six transplant centers in India were collected
and a total of 1540 transplants have been performed in a
country of over one billion population. At the center in
Vellore, from October 1986 to December 2006, a total of
626 transplants have been performed in 595 patients, with
28 patients having more than one transplant. Thalassemia
accounted for a third of these transplants: the country has
over 20 million carriers and 10 000 children are born
each year with thalassemia major. The average cost of
allogeneic BMT in India is around $15 000–20 000, and
this is considerably lower than the cost in the West. India
needs to develop more transplant centers with adequately
trained personnel, as there is great need for them.
Improvements in the economy mean that more patients
can afford this treatment.
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Introduction
India has a population of over one billion people with
about 5% being able to afford the very best treatment, 25%
in the middle class with increasing income and 70% who
cannot afford a transplant unless it is provided by the state,
and this is not likely considering other urgent health
priorities.1 With 20 million carriers for thalassemia and
10 000 children being born with thalassemia major each
year, if one-third of these patients have an HLA-matched
sibling donor, there is a potential to cure 3000 children with
BMT.2 If one considers six per million as the incidence of
aplastic anemia, there would be 6000 new cases/year, and if
10% of these patients are suitable candidates for trans-
plant, then the country would need to do 600 transplants
per year for this disease alone. India’s gross domestic
product (GDP) per capita in 1999 was $370 and in 2006,
this had risen to $3460 (source: World Population Data
Sheet 1999/2006). This means that many patients can now
afford to have a transplant even if resources are not
available from the state or private insurance.
The process of collecting information and maintaining a
database of transplant activity in India has not been
streamlined. In September 2005, data were collected from
six transplant centers in the country and their location is
given in Figure 1.
HLA typing
The first prerequisite for an allogeneic BMT program is
HLA typing: this is available in tertiary hospitals and
private laboratories. Serology is still performed for AB
(HLA class I typing of AB antigens) typing, but most
laboratories use DNA methods for DR (HLA class II
typing of DR antigens) typing. The Asian Indian Donor
Marrow Registry (AIDMR) is located in New Delhi with a
BM database of 3000 donors. High-resolution typing is
available at the AIDMR, but only one unrelated transplant
using cord blood from the NMDP has been performed so
far. There are a few private cord blood banks in India.
Transplant unit
Many hospitals in the West perform transplants in
standard single rooms. The much higher level of anti-
microbial resistance and poor quality of the environment in
developing countries make it prudent to have a dedicated
HEPA-filtered transplant unit where there is a high level of
control of the environment.
BMT data from India
In September 2005, data were collected from six transplant
centers in India and a total of 1540 transplants have been
performed in India at these centers (Table 1). Of these, half
were autologous transplants mainly for myeloma. As
further national data are not available, the rest of this
paper gives data on transplant activity at the Christian
Medical College, Vellore.
Transplant program at Vellore
Figure 2 shows the number of transplants performed and
the type and Figure 3 indicates the proportion of allogeneic
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transplants performed for thalassemia in relation to the
other diseases. Table 2 gives the distribution of diseases for
which a transplant has been performed.
Conditioning
For thalassemia, conditioning has been performed with
various combinations of BU and CY with or without
antilymphocyte globulin. Conditioning for leukemia has
been performed with the Tutschka protocol of BU 16mg/
kg and CY 120mg/kg. For aplastic anemia, we now use
mainly fludarabine-based conditioning3 and CY TBI is
used for ALL.
GVHD
CYA and short MTX are the main protocol for GVHD
with a target CYA level of 250 ng/ml.
Antimicrobial policies
Acyclovir is administered at a dose of 15mg/kg/day
i.v. starting day þ 1, is switched to oral dose after day 14
and is continued for 2–3 months. Most patients and donors
are CMV IgG-positive and ganciclovir is started when
the CMV-PCR becomes positive post transplant.
Trimethoprim sulfa and penicillin are given for 1-year post
transplant.
Tuberculosis
Records of 217 BMT patients during the period 1986–1999
were reviewed and mycobacterial infections were diagnosed
in three patients, (1.38%), all of whom presented with
extrapulmonary disease, and two of these patients had
disseminated disease.4 Infection with Mycobacterium
tuberculosis is not a common problem in allogeneic BM
recipients even in an endemic area, but when it occurs, it is
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Figure 1 Major BMT centers in India (2005).
Table 1 Transplant activity in India (September 2005)
Autologous Allogeneic Total
Christian Medical College Hospital, Vellore 117 522 639
Tata Memorial Hospital, Mumbai 90 178 268
All India Institute of Medical Sciences, New Delhi 144 66 210
Apollo Hospital, Chennai 159
Jaslok Hospital, Mumbai 49 19 70
Research and Referral Hospital of the Armed Forces, New Delhi 26 37 63
Sahayadri Hospital, Pune 7 59 66
Gujarat Cancer Research Center, Ahmedabad 32 0 32
Sanjay Gandhi Post Graduate Institute, Lucknow 25
Kidwai Memorial Hospital, Bangalore 3 0 3
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usually disseminated with predominantly extrapulmonary
involvement. On the basis of these data, we do not
use isonicotinic acid hydrazide prophylaxis, as it will
complicate the interpretation of abnormal liver function
tests post transplant.
Other infections
There were 415 documented infections among 304 trans-
plants: bacterial (34.9%), viral (42.9%), fungal (15.9%)
and other infections (6.3%), including tuberculosis.5
Bacterial pathogens were mainly Gram-negative bacteria
(80%) as compared with Gram-positive (20%) bacteria.
The common Gram-negative bacteria were nonfermenting
Gram-negative bacteria (24.9%), Pseudomonas (17.9%),
Escherichia coli (17.9%) and Klebsiella (9.7%). The major
source of positive cultures was blood (53.7%) followed
by urine (25.5%) and sputum (8.9%). In all, 133
of 304 (43.7%) transplants had 178 documented viral
infections. The common viral infections were due to
cytomegalovirus, herpes group of viruses and transfusion-
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Figure 2 BMT at Christian Medical College Hospital, Vellore (October 1986–December 2006).
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Figure 3 BMT at for thalassemia, compared with other indications. Christian Medical College Hospital, Vellore (October 1986–December 2006).
Table 2 Indications for BMT—Christian Medical College
Hospital, Vellore (October 1986–December 2006)
Diseases Patients Transplants BMT-1 BMT-2 BMT-3
Thalassemia 218 227 218 9 —
AML 107 111 107 4 —
ALL 39 39 39 — —
CML 91 99 91 7 1
Aplastic anemia 84 90 84 5 1
Fanconis anemia 8 10 8 1 1
Myelodysplasia 29 31 29 2 —
Miscellaneous 19 19 19 — —
Total 595 626 595 28 3
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related hepatitis; 60 of 304 (19.7%) transplants had
66 documented fungal infections. Common fungi included
Aspergillus species (69.7%), Candida (22.2%) and
Zygomycetes (8.1%).
BM harvest. For all thalassemia transplants, BM is the
stem cell source and we use sternal aspiration needles,
which result in little postoperative pain. For leukemia and
aplastic anemia, G-CSF-mobilized PBSC are preferred.
Chimerism
Engraftment and chimerism are documented with an
amylogenin PCR for sex-mismatched transplants and a
panel of short tandem repeats (STRs) and variable number
of tandem repeats (VNTRs). Gene scan is used for
quantification.6
BMT for thalassemia
From October 1991 to December 2006, 218 patients with
thalassemia were treated with an allogeneic BM transplant:
patients were risk-stratified by the criteria proposed by
Lucarelli: class I: 15 (6. 9%), class II: 78 (35.8%) and class
III: 125 (57.4%), and this is a reflection of the poor pre-
transplant care that these patients receive. With a mean
follow-up of 133 months (range: 6–183), 72 (80.8%) 89
children in class II are alive and well, free of transfusion
and of immunosuppression (Table 3). However, among the
114 patients who were in class III, there was a 34.4%
mortality and 19.4% rejection, which means that these
patients should receive better pre-transplant care and
should be taken early for BMT. Allogeneic BMT at
$15 000–20 000 is equivalent to the cost of 3 years of
transfusion and chelation and is a good alternative in the
developing world.
Allo-SCT in India costs around US$ 15 000–20 000, and
this is considerably lower than the cost in the West. It
therefore makes sense for the country to develop more
transplant centers, and with worldwide medical tourism on
the increase, India can (after providing for its own citizens)
be on the map for BMT.7,8
Data on all transplants at Christian Medical College
Hospital, Vellore are being reported to the CIBMTR.
Research activity revolves mainly around pharmacoki-
netics of BU and CY and conditioning regimens for
thalassemia.9,10
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